News Releases

Year

27 May '20

Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020

-- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Casey

PDF Version

12 May '20

Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update

— Interim analysis for the GAIN Trial on track for Q4 2020, with top-line results from study’s final analysis expected in Q4 2021 — Cortexyme shared additional scientific evidence supporting the gingipain hypothesis via multiple presentations and publications SOUTH SAN FRANCISCO, Calif.

PDF Version

07 May '20

Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020

-- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying

PDF Version

06 May '20

Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 6, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative

PDF Version

30 Apr '20

Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary

-- McDowell joins with over two decades of biopharma legal and strategic experience at development and commercial stage companies SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 30, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a biopharmaceutical company developing treatments for Alzheimer’s disease

PDF Version

06 Apr '20

Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020

-- Presentation to be webcast on Cortexyme’s website -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 6, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying

PDF Version

02 Apr '20

Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020

-- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology -- Cortexyme’s lead compound, COR388, targets gingipains produced by P. gingivalis and is currently under investigation in the Phase 2/3 GAIN Trial SOUTH SAN FRANCISCO, Calif.

PDF Version

17 Mar '20

Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

— Following initial public offering and private placement, Cortexyme is well capitalized and focused on high quality execution of the Phase 2/3 GAIN Trial — Interim analysis for the GAIN Trial on track to be completed before year-end 2020, with top-line results from study’s final analysis expected

PDF Version

16 Mar '20

Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients

- Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN FRANCISCO, Calif.

PDF Version

13 Feb '20

Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease

- Interim analysis in the Phase 2/3 GAIN Trial expected to occur in Q4 2020 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 13, 2020-- Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15